Eli Lilly (LLY) to acquire Ajax Therapeutics for up to USD 2.3bln in cash, and is to advance outcomes for patients with myelofibrosis and polycythemia vera

Eli Lilly's acquisition of Ajax Therapeutics for up to $2.3 billion underscores its strategic push into hematological conditions, notably myelofibrosis and polycythemia vera. This deal not only suggests confidence in the future of these therapies but could also influence investor sentiment in the pharmaceuticals sector as it signals a proactive stance in expanding their therapeutic portfolio, potentially impacting stock valuations and market dynamics in related sectors.